04-2028
|
A Phase 3, Multi-center, Randomized Withdrawal and Long-
A Phase 3, Multi-center, Randomized Withdrawal and Long-
|
03-2028
|
See Real-World Experience - Barostim¿ Advancing the Lev
See Real-World Experience - Barostim¿ Advancing the Lev
|
02-2028
|
A Randomized, Double-blind, Placebo-controlled Multicent
A Randomized, Double-blind, Placebo-controlled Multicent
|
01-2028
|
Long-Term Open-Label Study to Assess the Safety and Effi
Long-Term Open-Label Study to Assess the Safety and Effi
|
05-2026
|
An Open-label Study of the Long-term Safety and Tolerabi
An Open-label Study of the Long-term Safety and Tolerabi
|
04-2026
|
A Randomized, Double-Blind, Placebo-Controlled, 2-Period
A Randomized, Double-Blind, Placebo-Controlled, 2-Period
|
03-2026
|
Prospective, randomized, double-blind, placebo-controlle
Prospective, randomized, double-blind, placebo-controlle
|
02-2026
|
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO
|
02-2026
|
A Phase 1/2 Study of the Safety and Efficacy of LX2006 G
A Phase 1/2 Study of the Safety and Efficacy of LX2006 G
|
11-2025
|
A RANDOMIZED, PARALLEL-ARM, DOUBLE-BLIND, PLACEBO-CONTRO
A RANDOMIZED, PARALLEL-ARM, DOUBLE-BLIND, PLACEBO-CONTRO
|
03-2025
|
A Randomized, Placebo-Controlled, Double-Blind Study of
A Randomized, Placebo-Controlled, Double-Blind Study of
|
11-2024
|
Protocol #A4170
Protocol #A4170
|
11-2024
|
Protocol #RT001-006
Protocol #RT001-006
|
11-2024
|
A Phase 2 Double-Blind, Randomized, Placebo-Controlled,
A Phase 2 Double-Blind, Randomized, Placebo-Controlled,
|
10-2024
|
A Phase 2, Randomized, Double-Blind, Placebo-Controlled,
A Phase 2, Randomized, Double-Blind, Placebo-Controlled,
|
09-2024
|
A Phase 1, Blinded, Randomized, Placebo-controlled Study
A Phase 1, Blinded, Randomized, Placebo-controlled Study
|
08-2024
|
A Phase 2b, 12-week, Double-blind, Placebo-controlled, R
A Phase 2b, 12-week, Double-blind, Placebo-controlled, R
|
05-2024
|
An observational run-in study of adults with autosomal d
An observational run-in study of adults with autosomal d
|
03-2024
|
A Randomized, Participant, Investigator and Sponsor Blin
A Randomized, Participant, Investigator and Sponsor Blin
|
11-2023
|
Protocol #BHV4157-206
Protocol #BHV4157-206
|
08-2023
|
A DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVA
A DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVA
|
06-2023
|
Protocol: BK-JM-201
Protocol: BK-JM-201
|
11-2022
|
Protocol #ADX48621-301
Protocol #ADX48621-301
|
11-2022
|
Protocol #: Synchrony-1
Protocol #: Synchrony-1
|
11-2022
|
Protocol #M15-563
Protocol #M15-563
|
10-2022
|
An Open-label Safety Study of Dipraglurant (ADX48621) in
An Open-label Safety Study of Dipraglurant (ADX48621) in
|
06-2022
|
Medtronic Fellowship 2021-2022
Medtronic Fellowship 2021-2022
|
06-2022
|
Clinical Trial Readiness for SCA1 and SCA3
Clinical Trial Readiness for SCA1 and SCA3
|
06-2022
|
Protocol #217-ETD-201
Protocol #217-ETD-201
|
04-2022
|
Protocol #BHV3241-301
Protocol #BHV3241-301
|
04-2022
|
Protocol #M15-562
Protocol #M15-562
|
02-2022
|
Protocol #PL101-LID201
Protocol #PL101-LID201
|
11-2021
|
Protocol #Vercise DBS A4069
Protocol #Vercise DBS A4069
|
10-2021
|
Protocol #B7601011
Protocol #B7601011
|
08-2021
|
Protocol #NAF CRC-SCA
Protocol #NAF CRC-SCA
|
06-2021
|
Protocol #ET-14
Protocol #ET-14
|
06-2020
|
2019-2020 Boston Scientific Fellowship Grant
2019-2020 Boston Scientific Fellowship Grant
|
06-2020
|
Medtronic Fellowship Grant
Medtronic Fellowship Grant
|
06-2020
|
Protocol #TAK-831-1501
Protocol #TAK-831-1501
|
05-2020
|
Protocol #CX-8998-CLN2-001
Protocol #CX-8998-CLN2-001
|
03-2020
|
Protocol #ADS-AMT-PD302
Protocol #ADS-AMT-PD302
|
03-2020
|
Protocol #ADS-AMT-PD304
Protocol #ADS-AMT-PD304
|
01-2020
|
Protocol #CN002-012
Protocol #CN002-012
|
10-2019
|
Protocol #IVIG
Protocol #IVIG
|
06-2019
|
2018-2019 Boston Scientific Fellowship Grant - Wai Wai Miller
2018-2019 Boston Scientific Fellowship Grant - Wai Wai Miller
|
05-2019
|
Protocol #BHV4157-201
Protocol #BHV4157-201
|
05-2019
|
Protocol #CN002004
Protocol #CN002004
|
06-2018
|
Protocol #CN002003
Protocol #CN002003
|
06-2018
|
Protocol #RTMOTION-001
Protocol #RTMOTION-001
|
05-2018
|
Protocol #FARA Gait and Balance Study
Protocol #FARA Gait and Balance Study
|
05-2018
|
Protocol #408-C-1402
Protocol #408-C-1402
|
05-2018
|
Protocol #RT001-002
Protocol #RT001-002
|
07-2017
|
Protocol #OS320-3005
Protocol #OS320-3005
|
07-2017
|
Protocol #OS320-3006
Protocol #OS320-3006
|
06-2017
|
Protocol #Sagene 2014
Protocol #Sagene 2014
|
03-2017
|
Protocol #SNC102-201
Protocol #SNC102-201
|
10-2016
|
Protocol #VP20629-100
Protocol #VP20629-100
|
09-2016
|
Protocol #EPI-743 PM
Protocol #EPI-743 PM
|
09-2016
|
Protocol #ICARS-CGI-Ery01-2013
Protocol #ICARS-CGI-Ery01-2013
|
07-2016
|
Protocol #EPI-743
Protocol #EPI-743
|
12-2015
|
Immunophenotyping of LRRK2 Mutation Carriers
Immunophenotyping of LRRK2 Mutation Carriers
|
11-2015
|
Protocol #FARA
Protocol #FARA
|
11-2015
|
Protocol# EPI-2010-006
Protocol# EPI-2010-006
|
11-2015
|
Protocol #PD0004
Protocol #PD0004
|
07-2015
|
Protocol#RL0003
Protocol#RL0003
|
03-2015
|
Protocol #BVF-025-201
Protocol #BVF-025-201
|
07-2014
|
Protocol#AL-108-231
Protocol#AL-108-231
|
06-2014
|
Protocol#ROP111569
Protocol#ROP111569
|
06-2014
|
Protocol#ROP111569
Protocol#ROP111569
|
06-2014
|
Protocol#ROP111662
Protocol#ROP111662
|
05-2013
|
Blinded, Randomized, Comparative Study of Gabapentin and Gabapentin Enacarbil in Patients with Restless Leg Syndrome
Blinded, Randomized, Comparative Study of Gabapentin and Gabapentin Enacarbil in Patients with Restless Leg Syndrome
|
12-2012
|
Friedreich's Ataxia Research Center
Friedreich's Ataxia Research Center
|
08-2012
|
Protocol # VESI-9C01
Protocol # VESI-9C01
|
07-2012
|
Protocol #GA00813T
Protocol #GA00813T
|
03-2012
|
Natural History Biomarkers in Friedreich's Ataxia
Natural History Biomarkers in Friedreich's Ataxia
|
08-2011
|
Clinical Research Consortium for Spinocerebellar A
Clinical Research Consortium for Spinocerebellar A
|
08-2011
|
Clinical Research Consortium for Spinocerebellar Ataxias
Clinical Research Consortium for Spinocerebellar Ataxias
|
06-2011
|
Validation of the TRG Essential Tremor Rating Scal
Validation of the TRG Essential Tremor Rating Scal
|
12-2010
|
Clinical Outcome Measures in Friedreich's Ataxia
Clinical Outcome Measures in Friedreich's Ataxia
|
09-2010
|
Protocol # GA3051Y3CS
Protocol # GA3051Y3CS
|
06-2010
|
A Pilot, Randomized, Double-blind, Placebo-Controlled Phase I Study to Determine the Safety and Tolerability of Varenicline (Chantix) in Treating Spinocerebellat Ataxia Types 1, 2, 3, and 6.
A Pilot, Randomized, Double-blind, Placebo-Controlled Phase I Study to Determine the Safety and Tolerability of Varenicline (Chantix) in Treating Spinocerebellat Ataxia Types 1, 2, 3, and 6.
|
05-2010
|
EMD62-225-030 PADDY 0
EMD62-225-030 PADDY 0
|
01-2010
|
Protocol #07-021L
Protocol #07-021L
|
09-2009
|
Double-blind, Randomized, Placebo-Controlled Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia
Double-blind, Randomized, Placebo-Controlled Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia
|
03-2009
|
Serono/Protocol #IMP24735
Serono/Protocol #IMP24735
|
10-2008
|
Wellness Health & Pharmacy/Protocol GSH
Wellness Health & Pharmacy/Protocol GSH
|
06-2008
|
Protocol #S308.3.004
Protocol #S308.3.004
|
06-2008
|
Protocol #S308.3.009
Protocol #S308.3.009
|
02-2008
|
248-538
248-538
|
01-2008
|
Protocol #PO413580 BIPI 248.622
Protocol #PO413580 BIPI 248.622
|
01-2008
|
Protocol # 1198.100
Protocol # 1198.100
|
05-2007
|
Protocol #ELC200 A2305
Protocol #ELC200 A2305
|
06-2006
|
Protocol #101468/228
Protocol #101468/228
|
01-2006
|
Monitoring Force USA/Merck - Protocol #EMR 62 225 019
Monitoring Force USA/Merck - Protocol #EMR 62 225 019
|
10-2005
|
TEVA Pharmaceuticals/Protocol #TVP 1012/135
TEVA Pharmaceuticals/Protocol #TVP 1012/135
|
03-2004
|
Monitoring Force USA/Merck
Monitoring Force USA/Merck
|